Groundbreaking research indicates that popular weight-loss medications like Ozempic, Wegovy, and Mounjaro might have far-reaching applications beyond obesity treatment, potentially revolutionising the approach to various chronic conditions.
Dr Mo Sarhan, a Florida-based physician, has witnessed remarkable success using Eli Lilly’s Mounjaro to treat patients with opioid and alcohol addictions. His team has administered glucagon-like peptide-1 receptor agonists (GLP-1s) to approximately 75 patients, yielding what he describes as “compelling” results.
Eli Lilly’s chief executive, Dave Ricks, has announced the company’s plans to launch extensive studies investigating GLP-1s’ effectiveness in treating alcohol, nicotine, and drug abuse. This marks the first major pharmaceutical company to explore these applications systematically.
The market potential for these drugs is substantial, with Goldman Sachs analysts projecting a £130 billion market by 2030. Novo Nordisk is currently conducting three late-stage trials of semaglutide for Alzheimer’s disease, whilst early studies suggest promise in treating Parkinson’s disease symptoms.
The therapeutic mechanisms remain partially unclear, though research indicates the drugs may influence pleasure pathways in the brain similarly to how they suppress appetite. Beyond weight loss, GLP-1s have demonstrated impressive cardiovascular benefits, with studies showing a 28 per cent reduction in heart attack risk.
Despite the promising outlook, challenges persist. The current high cost of these medications – approximately £1,349 per month in the US – poses a significant barrier to widespread adoption. Additionally, side effects including nausea and fatigue have led to a 30 per cent discontinuation rate within the first month of use.
The pharmaceutical industry’s focus remains primarily on the lucrative obesity market, potentially limiting research into other applications. However, as understanding of these drugs grows and more affordable options emerge, they could transform the treatment landscape for numerous chronic conditions.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.